Argenx
ARGX
#402
Rank
S$75.09 B
Marketcap
S$1,194
Share price
-1.73%
Change (1 day)
-0.13%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): S$28.86

According to Argenx 's latest financial reports the company's current EPS (TTM) is S$28.84. In 2025 the company made an earnings per share (EPS) of S$27.19 an increase over its 2024 EPS that were of S$17.96.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)S$28.866.14%
2025S$27.1951.44%
2024S$17.96-369.77%
2023S-$6.66-60.46%
2022S-$16.8363.33%
2021S-$10.31-40.37%
2020S-$17.29183.47%
2019S-$6.10123.09%
2018S-$2.7354.93%
2017S-$1.7614.07%
2016S-$1.5513.05%
2015S-$1.37-36.34%
2014S-$2.15209.04%
2013S-$0.70-33.99%
2012S-$1.05185.59%
2011S-$0.37